MX2020003473A - Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. - Google Patents
Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.Info
- Publication number
- MX2020003473A MX2020003473A MX2020003473A MX2020003473A MX2020003473A MX 2020003473 A MX2020003473 A MX 2020003473A MX 2020003473 A MX2020003473 A MX 2020003473A MX 2020003473 A MX2020003473 A MX 2020003473A MX 2020003473 A MX2020003473 A MX 2020003473A
- Authority
- MX
- Mexico
- Prior art keywords
- viral
- treatment
- inhibitor
- bacterial infections
- infection
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title abstract 5
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 5
- 208000036142 Viral infection Diseases 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 230000003612 virological effect Effects 0.000 title abstract 2
- 229940124647 MEK inhibitor Drugs 0.000 title 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title 1
- 230000009385 viral infection Effects 0.000 abstract 3
- 208000003322 Coinfection Diseases 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 241000712461 unidentified influenza virus Species 0.000 abstract 2
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU100487 | 2017-10-17 | ||
| PCT/EP2018/078335 WO2019076947A1 (en) | 2017-10-17 | 2018-10-17 | NEW MEK INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003473A true MX2020003473A (es) | 2020-10-01 |
Family
ID=60484427
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003473A MX2020003473A (es) | 2017-10-17 | 2018-10-17 | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. |
| MX2022016066A MX2022016066A (es) | 2017-10-17 | 2020-07-13 | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016066A MX2022016066A (es) | 2017-10-17 | 2020-07-13 | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11903917B2 (OSRAM) |
| EP (2) | EP3697405B1 (OSRAM) |
| JP (3) | JP7227967B2 (OSRAM) |
| KR (1) | KR102848960B1 (OSRAM) |
| CN (2) | CN111479566B (OSRAM) |
| AU (2) | AU2018351475A1 (OSRAM) |
| BR (1) | BR112020007442A2 (OSRAM) |
| CA (1) | CA3078424A1 (OSRAM) |
| CY (1) | CY1124507T1 (OSRAM) |
| DK (1) | DK3697405T3 (OSRAM) |
| EA (1) | EA202090693A1 (OSRAM) |
| ES (2) | ES3041322T3 (OSRAM) |
| HR (1) | HRP20211252T1 (OSRAM) |
| HU (1) | HUE055738T2 (OSRAM) |
| LT (1) | LT3697405T (OSRAM) |
| MX (2) | MX2020003473A (OSRAM) |
| PL (1) | PL3697405T3 (OSRAM) |
| PT (1) | PT3697405T (OSRAM) |
| SI (1) | SI3697405T1 (OSRAM) |
| WO (1) | WO2019076947A1 (OSRAM) |
| ZA (1) | ZA202002069B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3697405T (pt) * | 2017-10-17 | 2021-08-27 | Atriva Therapeutics Gmbh | Novo inibidor de mek para o tratamento de infeções virais e bacterianas |
| LU101183B1 (en) * | 2019-04-16 | 2020-10-16 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| CN114667138A (zh) * | 2019-08-27 | 2022-06-24 | 归属疗法有限公司 | Mek抑制剂与帽状结构依赖型核酸内切酶抑制剂的组合 |
| KR20220079573A (ko) * | 2019-10-08 | 2022-06-13 | 아트리바 테라퓨틱스 게엠베하 | 한타바이러스 감염의 치료를 위한 mek 억제제 |
| EP3912623B1 (en) * | 2020-05-20 | 2024-07-31 | Atriva Therapeutics GmbH | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
| CN112957361B (zh) * | 2021-03-24 | 2022-07-29 | 中国科学院武汉病毒研究所 | 曲美替尼在制备抗沙粒病毒的抗病毒制剂中的应用 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| HUP0104933A3 (en) * | 1999-01-07 | 2003-12-29 | Warner Lambert Co | Antiviral method using mek inhibitors |
| PL352684A1 (pl) | 1999-07-16 | 2003-09-08 | Warner-Lambert Company | Sposób leczenia chronicznego bólu z użyciem inhibitorów MEK |
| DE10017480A1 (de) | 2000-04-07 | 2001-10-11 | Transmit Technologietransfer | Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren |
| JP2005515253A (ja) | 2002-01-23 | 2005-05-26 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Ｎ−（４−置換フェニル）−アントラニル酸ヒドロキサメートエステル |
| DE10300222A1 (de) * | 2003-01-03 | 2004-07-15 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen |
| JP2007055983A (ja) * | 2005-08-26 | 2007-03-08 | Tokyo Univ Of Science | 細胞内に侵入した病原性細菌に起因する疾患の予防・改善剤 |
| KR20130113430A (ko) | 2010-08-05 | 2013-10-15 | 케이스 웨스턴 리저브 유니버시티 | 신경 연결의 발달 장애에 대한 ｅｒｋ 억제제 |
| JP6294889B2 (ja) * | 2012-10-08 | 2018-03-14 | アトリバ セラピューティクス ゲーエムベーハー | ウイルス疾患の処置におけるｍｅｋ阻害物質 |
| CN113398271A (zh) | 2014-05-16 | 2021-09-17 | 归属疗法有限公司 | 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略 |
| PT3697405T (pt) * | 2017-10-17 | 2021-08-27 | Atriva Therapeutics Gmbh | Novo inibidor de mek para o tratamento de infeções virais e bacterianas |
| KR20220079573A (ko) | 2019-10-08 | 2022-06-13 | 아트리바 테라퓨틱스 게엠베하 | 한타바이러스 감염의 치료를 위한 mek 억제제 |
| EP3912623B1 (en) | 2020-05-20 | 2024-07-31 | Atriva Therapeutics GmbH | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
-
2018
- 2018-10-17 PT PT188000459T patent/PT3697405T/pt unknown
- 2018-10-17 BR BR112020007442-0A patent/BR112020007442A2/pt active Search and Examination
- 2018-10-17 KR KR1020207013451A patent/KR102848960B1/ko active Active
- 2018-10-17 LT LTEPPCT/EP2018/078335T patent/LT3697405T/lt unknown
- 2018-10-17 US US16/756,720 patent/US11903917B2/en active Active
- 2018-10-17 ES ES21185183T patent/ES3041322T3/es active Active
- 2018-10-17 JP JP2020521541A patent/JP7227967B2/ja active Active
- 2018-10-17 ES ES18800045T patent/ES2883639T3/es active Active
- 2018-10-17 DK DK18800045.9T patent/DK3697405T3/da active
- 2018-10-17 CA CA3078424A patent/CA3078424A1/en active Pending
- 2018-10-17 HR HRP20211252TT patent/HRP20211252T1/hr unknown
- 2018-10-17 AU AU2018351475A patent/AU2018351475A1/en not_active Abandoned
- 2018-10-17 WO PCT/EP2018/078335 patent/WO2019076947A1/en not_active Ceased
- 2018-10-17 HU HUE18800045A patent/HUE055738T2/hu unknown
- 2018-10-17 EA EA202090693A patent/EA202090693A1/ru unknown
- 2018-10-17 EP EP18800045.9A patent/EP3697405B1/en active Active
- 2018-10-17 PL PL18800045T patent/PL3697405T3/pl unknown
- 2018-10-17 CN CN201880081184.5A patent/CN111479566B/zh active Active
- 2018-10-17 CN CN202410133936.5A patent/CN118141795A/zh active Pending
- 2018-10-17 SI SI201830351T patent/SI3697405T1/sl unknown
- 2018-10-17 MX MX2020003473A patent/MX2020003473A/es unknown
- 2018-10-17 EP EP21185183.7A patent/EP3973960B1/en active Active
-
2020
- 2020-05-04 ZA ZA2020/02069A patent/ZA202002069B/en unknown
- 2020-07-13 MX MX2022016066A patent/MX2022016066A/es unknown
-
2021
- 2021-08-24 CY CY20211100757T patent/CY1124507T1/el unknown
-
2023
- 2023-02-10 JP JP2023018912A patent/JP7618276B2/ja active Active
-
2024
- 2024-02-16 US US18/443,904 patent/US20240245637A1/en active Pending
- 2024-08-16 AU AU2024205853A patent/AU2024205853A1/en active Pending
- 2024-12-25 JP JP2024228526A patent/JP2025031917A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003473A (es) | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. | |
| CL2017001798A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas. | |
| WO2017191258A8 (en) | INFLUENZA MRNA VACCINES | |
| CL2016002179A1 (es) | Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b. | |
| GT201300093A (es) | Compuestos antivirales | |
| CL2015003298A1 (es) | Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
| PH12017500207B1 (en) | Indoles for use in influenza virus infection | |
| DOP2016000336A (es) | Derivados de isoindolina para uso en el tratamiento de una infeccion viral | |
| CL2016000493A1 (es) | Inhibidores de polimerasa hcv. | |
| EA201692303A1 (ru) | Новая противоинфекционная стратегия против коинфекций, вызванных вирусом гриппа и s.aureus | |
| BR112018009009A2 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
| CL2022000531A1 (es) | Composiciones y métodos para el tratamiento de infecciones virales. | |
| PH12017500393A1 (en) | Pyrrolopyrimidines for use in influenza virus infection | |
| ECSP18061667A (es) | Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza | |
| BR112018071048A2 (pt) | combinações e métodos que compreendem um inibidor da montagem de capsídeos | |
| MX2017011655A (es) | Compuestos de aza-piridona y usos de estos. | |
| MX2017003117A (es) | Particula tipo virus de flavivirus. | |
| MX380393B (es) | Vectores atenuados de influenza para la prevencion y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncologicas. | |
| CO2022014031A2 (es) | Compuestos para su uso en infecciones víricas | |
| CR20160178A (es) | Derivados de desoxinojirimicina y sus métodos de uso | |
| MX2021012604A (es) | Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas. | |
| UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
| CL2015003752A1 (es) | Inhibidores de replicación viral, su proceso de preparación y sus uso terapeutico | |
| CL2016001977A1 (es) | Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias. | |
| JOP20190214A1 (ar) | ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها |